RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stock Position Lifted by Barclays PLC

Barclays PLC lifted its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 277.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 39,729 shares of the company’s stock after acquiring an additional 29,195 shares during the quarter. Barclays PLC’s holdings in RAPT Therapeutics were worth $79,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after buying an additional 706,900 shares during the period. Federated Hermes Inc. lifted its position in RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after purchasing an additional 520,368 shares during the last quarter. Acadian Asset Management LLC boosted its stake in RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares during the period. Cubist Systematic Strategies LLC grew its position in RAPT Therapeutics by 826.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after purchasing an additional 263,372 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in shares of RAPT Therapeutics by 138.1% during the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after buying an additional 116,853 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Price Performance

NASDAQ RAPT opened at $1.45 on Friday. RAPT Therapeutics, Inc. has a 12 month low of $0.79 and a 12 month high of $27.35. The company has a market capitalization of $50.69 million, a P/E ratio of -0.52 and a beta of 0.07. The company’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $2.07.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, analysts anticipate that RAPT Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RAPT. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Thursday, December 26th. Stifel Nicolaus restated a “hold” rating and set a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, Wells Fargo & Company decreased their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.56.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.